BVXV BiondVax Pharmaceuticals Ltd. Stock Quote

BVXV [NASD]

Index	-	P/E	-	EPS (ttm)	-0.45	Insider Own	29.84%	Shs Outstand	13.97M	Perf Week	-2.50%
Market Cap	42.81M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	11.12M	Perf Month	4.00%
Income	-1.70M	PEG	-	EPS next Q	-	Inst Own	2.00%	Short Float	3.88%	Perf Quarter	-26.76%
Sales	-	P/S	-	EPS this Y	97.00%	Inst Trans	29.19%	Short Ratio	3.28	Perf Half Y	-3.11%
Book/sh	-0.41	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-84.55%
Cash/sh	0.21	P/C	14.76	EPS next 5Y	-	ROE	15.60%	52W Range	2.35 - 62.00	Perf YTD	11.03%
Dividend	-	P/FCF	-	EPS past 5Y	36.40%	ROI	-	52W High	-94.97%	Beta	2.26
Dividend %	-	Quick Ratio	0.20	Sales past 5Y	-	Gross Margin	-	52W Low	32.77%	ATR	0.18
Employees	17	Current Ratio	0.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	51.77	Volatility	4.89% 5.72%
Optionable	No	Debt/Eq	-	EPS Q/Q	67.90%	Profit Margin	-	Rel Volume	0.41	Prev Close	3.08
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	131.68K	Price	3.12
Recom	-	SMA20	2.58%	SMA50	1.28%	SMA200	-69.51%	Volume	54,211	Change	1.30%

Jun-15-21 03:23PM	BiondVax Pharmaceuticals Ltd. (BVXV): Hedge Funds Are Snapping Up Insider Monkey
May-13-21 04:54PM	BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update PR Newswire
Mar-23-21 07:44AM	Letter from BiondVax's New CEO to Shareholders PR Newswire
Feb-10-21 04:30PM	BiondVax Announces Exercise in Full of Underwriter's Over-Allotment Option in Follow-on Offering PR Newswire
Feb-03-21 02:45PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $12.1 Million Follow-On Offering for BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV) ACCESSWIRE
Feb-02-21 04:30PM	BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering PR Newswire
Jan-29-21 07:57AM	BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares PR Newswire -17.27%
Jan-28-21 06:48PM	BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares PR Newswire
03:23PM	BiondVax Announces Third Quarter 2020 Financial Results & Business Update PR Newswire
Jan-21-21 07:15AM	BiondVax Announces Appointment of Amir Reichman as New CEO PR Newswire +40.66%
Oct-23-20 05:03PM	Why BiondVax Pharmaceuticals Stock Imploded Today Motley Fool -86.27%
12:28PM	/C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./ PR Newswire
Oct-02-20 06:00AM	BiondVax Announces At-The-Market (ATM) Equity Offering Program PR Newswire
Aug-31-20 06:15AM	BVXV: Phase 3 Data for Universal Flu Vaccine in Late September to Late October 2020 Zacks Small Cap Research
Aug-20-20 04:01PM	BiondVax Announces Second Quarter 2020 Financial Results PR Newswire
Aug-13-20 04:01PM	BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update PR Newswire
Jul-01-20 06:00AM	Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial PR Newswire
Jun-30-20 04:01PM	BiondVax Announces First Quarter 2020 Financial Results PR Newswire
Jun-16-20 08:57AM	BVXV: Positive Results in NIH-Sponsored Phase 2 Trial of M-001; Raising Valuation to $81 Zacks Small Cap Research
Jun-12-20 08:00AM	BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update PR Newswire +10.74%
Jun-10-20 07:00AM	NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved PR Newswire +10.33%
May-20-20 06:30AM	BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants PR Newswire
May-09-20 08:47AM	How BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Can Impact Your Portfolio Volatility Simply Wall St.
May-04-20 06:30AM	BiondVax Announces Upcoming Expiration of Public Warrants PR Newswire +16.79%
Mar-24-20 04:01PM	New Directors Elected to BiondVax's Board of Directors PR Newswire
Mar-19-20 07:15AM	BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial PR Newswire +8.50%
Feb-05-20 01:00PM	Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials PR Newswire
Jan-16-20 03:05PM	BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis PR Newswire -6.48%
Dec-04-19 08:25AM	BVXV: Cohort 2 of Pivotal Phase 3 Universal Influenza Vaccine Trial Fully Enrolled Zacks Small Cap Research
Nov-26-19 07:00AM	BiondVax Announces Third Quarter 2019 Financial Results and Business Update PR Newswire
Nov-18-19 07:15AM	Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial PR Newswire
Nov-11-19 08:14AM	Do Directors Own BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Shares? Simply Wall St. +6.02%
Oct-07-19 09:15AM	BiondVax Receives 4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial PR Newswire
Aug-28-19 07:45AM	BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results PR Newswire
Aug-01-19 10:00AM	BVXV: Raises $20 Million; Phase 3 Trial Fully Funded Zacks Small Cap Research
Jul-16-19 07:30AM	BiondVax Announces Rights Offering Fully Subscribed at US$20 Million PR Newswire
Jul-08-19 05:45AM	First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial PR Newswire
Jun-26-19 10:51AM	European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to 24million PR Newswire
Jun-25-19 09:37AM	BiondVax Gets OK to Build Plant in Israel (BVXV) Investopedia
Jun-18-19 06:30AM	Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan PR Newswire
Jun-12-19 03:30PM	BVXV: Rights Offering to Finance Company Through Phase 3 Trial Results Zacks Small Cap Research
Jun-10-19 08:18AM	BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process PR Newswire
May-30-19 07:10AM	BiondVax Announces First Quarter 2019 Financial Results PR Newswire -7.51%
May-13-19 07:00AM	BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference PR Newswire
Apr-30-19 04:01PM	BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update PR Newswire
Apr-22-19 08:10AM	European Investment Bank (EIB) Extends Financing Agreement to 24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial PR Newswire -5.96%
Apr-17-19 01:00PM	BVXV: Update on Phase 3 Clinical Trial of Universal Influenza Vaccine Zacks Small Cap Research
Apr-15-19 07:50AM	BiondVax Universal Flu Vaccine Patent Application Accepted in Australia PR Newswire
Mar-28-19 07:30AM	BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference PR Newswire +5.90%
Mar-21-19 07:00AM	Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate PR Newswire
Nov-28-18 07:40AM	Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-26-18 07:00AM	BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate PR Newswire -7.25%
Nov-20-18 11:00AM	BVXV: Enrollment of First Season Cohort Complete in Phase 3 Trial of Universal Influenza Vaccine Zacks Small Cap Research
Nov-19-18 07:00AM	BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results PR Newswire
Nov-13-18 04:01PM	BiondVax Announces Third Quarter 2018 Financial Results PR Newswire
Oct-24-18 07:00AM	BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants PR Newswire
Oct-22-18 08:00AM	BiondVax Receives 8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial PR Newswire
Oct-17-18 08:15AM	Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Sep-05-18 09:30AM	BVXV: Phase 3 Trial of M-001 Underway Zacks Small Cap Research
Sep-04-18 06:15AM	BiondVax to Present at Influenza 2018 Oxford Conference PR Newswire
Aug-22-18 07:00AM	BiondVax Announces Second Quarter 2018 Financial Results PR Newswire +5.83%
Aug-20-18 07:50AM	Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:00AM	BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility PR Newswire
Aug-14-18 06:00AM	BiondVax Receives Second 6M Tranche Disbursement From the European Investment Bank (EIB) PR Newswire
Aug-08-18 08:30AM	First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial PR Newswire
Jun-28-18 07:00AM	Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors PR Newswire
Jun-19-18 09:00AM	BiondVax Receives Its First 6M Tranche Disbursement From the European Investment Bank (EIB) PR Newswire
Jun-05-18 07:45AM	Factors of Influence in 2018, Key Indicators and Opportunity within BiondVax Pharmaceuticals, MercadoLibre, 1-800 FLOWERS.COM, Redhill Biopharma, Mountain Province Diamonds, and Rhythm Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Jun-01-18 10:30AM	BVXV: Increased Media Coverage for M-001 Ahead of Phase 3 Clinical Trial Zacks Small Cap Research
May-29-18 07:00AM	BiondVax Announces First Quarter 2018 Financial Results PR Newswire
May-07-18 09:45AM	BVXV: Set to Initiate Phase 3 Clinical Trial of Universal Influenza Vaccine Candidate in 2H18 Zacks Small Cap Research
Apr-30-18 04:05PM	BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update PR Newswire
Apr-13-18 07:20AM	Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US ACCESSWIRE
Apr-12-18 06:30AM	BiondVax to Present at Universal Influenza Vaccines Conference PR Newswire
Apr-11-18 07:45AM	BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States PR Newswire
Apr-09-18 08:15AM	Recent Analysis Shows Norbord, BiondVax Pharmaceuticals, NXP Semiconductors N.V, Lazard, Canadian Solar, and Sierra Wireless Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-15-18 08:25AM	Recent Analysis Shows KB Financial Group, Southern Missouri, Net 1 UEPS Technologies, Financial Engines, Carbonite, and BiondVax Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-13-18 09:00AM	BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate PR Newswire
Feb-08-18 08:30AM	BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference PR Newswire
Jan-02-18 09:00AM	BiondVax Universal Flu Vaccine Patent Granted in India PR Newswire
Dec-27-17 09:00AM	BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA) PR Newswire
Dec-12-17 12:00PM	BVXV: Planning Continues for M-001 Phase 3 Program Zacks Small Cap Research
Dec-11-17 07:30AM	Blog Exposure - Synlogic And Ginkgo Bioworks Collaborate to Discover and Develop New Medicines for Neurological and Liver Disorders ACCESSWIRE
Dec-05-17 09:00AM	BiondVax's CEO Issues Letter to Shareholders PR Newswire
Nov-28-17 09:00AM	BiondVax Provides Third Quarter 2017 Financial Results and Update PR Newswire
Nov-20-17 09:00AM	BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine PR Newswire
Sep-20-17 01:00PM	BVXV: Raises $10 Million to Help Support M-001 Pivotal P3 Program as Standalone Universal Influenza Vaccine Zacks Small Cap Research
Sep-18-17 11:35AM	BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option PR Newswire
Sep-13-17 08:25PM	BiondVax Announces Pricing of Public Offering of American Depositary Shares PR Newswire
04:55PM	BiondVax Announces Public Offering of American Depositary Shares PR Newswire
11:07AM	Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)? Simply Wall St.
Sep-12-17 07:15AM	Featured Company News - Oncobiologics Announces Partnership with GMS Tenshi Holdings; Set to Accelerate the Commercialization of Biosimilar Candidates ACCESSWIRE
Aug-31-17 07:30AM	Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange PR Newswire
07:30AM	BiondVax Provides Second Quarter 2017 Financial Results and Update PR Newswire
Aug-14-17 08:00AM	BiondVax Receives Additional Grant Funding PR Newswire
Aug-01-17 01:00PM	BVXV: Positive Results From Phase 2b Trial of M-001; Ready to Move Into Pivotal P3 Trial as Standalone Universal Influenza Vaccine Zacks Small Cap Research
Jul-20-17 06:30AM	BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine PR Newswire
Jul-18-17 07:30AM	BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine PR Newswire
Jul-06-17 01:00PM	BVXV: Secures $22 Million Loan Agreement with European Investment Bank Zacks Small Cap Research
Jun-28-17 04:01PM	BiondVax's CEO Provides First Half 2017 General Corporate Update PR Newswire

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience